Evidence map›Paper›PMID 37689628›Full record

ArticleBMC women's health2023

Knowledge and perceptions about Dolutegravir and Dolutegravir counselling: a qualitative study among women living with HIV.

John C Chapola, Fan Lee, Agatha Bula, Nora E Rosenberg, Jennifer Tseka, Maganizo Chagomerana, Mina C Hosseinipour, Jennifer Hui-Yu Tang

Open access · goldAbstract read
In one paragraph

Article in BMC women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

John C ChapolaUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi. johnchapola@gmail.com.
Fan LeeDuke University, Durham, NC, USA.
Agatha BulaUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Nora E RosenbergUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Jennifer TsekaUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Maganizo ChagomeranaUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Mina C HosseinipourUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
Jennifer Hui-Yu TangUniversity of North Carolina Project-Malawi, Lilongwe Private Bag A104, Lilongwe, Malawi.
University of North Carolina at Chapel Hill · USDepartment of Health · ZADuke University · US

Funding

Malawi HIV Implementation Research Scientist Training Program (MHIRST)D43TW010060 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MINA CHRISTINE HOSSEINIPOUR, Victor Mwapasa · 2015 to 2026
$3.8M
Malawi Cancer Outcomes Research Program (M-CORP)D43CA260641 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHINULA, LAMECK, FEDORIW, YURI · 2021 to 2025
$1.3M
FIC NIH HHS D43 TW010060NCI NIH HHS D43 CA260641
6 · The paper itself

Abstract

introductionIn 2018, the Malawi Ministry of Health adopted the recommendation to switch first-line antiretroviral therapy (ART) from an efavirenz (EFV)-based to a dolutegravir (DTG)-based regimen. Little is known about patients' experience during this transition. We conducted a qualitative study to explore DTG-related counselling challenges among providers of HIV care and factors influencing regimen switching or non-switching among women living with HIV in Lilongwe, Malawi.

methodsBetween February-July 2020, we recruited participants who took part in DTG counselling on reasons to switch, side effects, and benefits from two government health facilities providing HIV care: Area 18 health centre and Bwaila district hospital in Lilongwe, Malawi. We purposively sampled and interviewed 8 women living with HIV who remained on an EFV-based regimen after counselling, 10 women who switched to a DTG-based regimen, and 10 HIV care providers who provided counselling about ART switching. In-depth interviews were used to explore patient's perceptions of DTG, factors affecting the decision to switch, and both patient and provider experience with counselling. Interview data was coded for themes using inductive and deductive codes. Interviews were conducted until thematic saturation was achieved. Data matrices were used for analysis and thematic extraction.

resultsMost women in both groups were well versed on DTG's potential side effects and felt well counselled on the benefits of switching, such as quicker viral load suppression. Many women associated DTG with birth defects and expressed concern. However, the primary reason for not switching was concern with how the new medication would be tolerated, especially when they were satisfied with their current regimen. Almost all providers expressed difficulty providing DTG counselling. Primary reasons included feeling inadequately trained and/or not having resources to use during counselling, such as diagrams or brochures.

conclusionDTG counselling was well accepted by women; however, some felt that their concerns were not fully addressed. Providers reflected this sentiment in that they did not feel adequately trained or well-equipped to provide adequate counselling. Training on counselling for new ART regimens should be intensified and utilize patient-centered educational materials to address the concerns raised by both patients and health care providers.

Indexed as

Drug-Related Side Effects and Adverse ReactionsHIV InfectionsAlkynesAnti-Retroviral AgentsBenzoxazinesCounselingCyclopropanesDolutegravirFemaleHumansAlkynesAnti-Retroviral AgentsBenzoxazinesCyclopropanesDolutegravirefavirenzAdherenceAntiretroviral therapyDolutegravirEfavirenzNeural tube defects

Identifiers

PMID37689628
PMCPMC10492391
OpenAlexW4386569664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.